布地奈德对感染诱发哮喘急性发作患儿趋化素样因子-1水平及免疫功能的影响

doi:10.11852/zgetbjzz2019-0004

摘要/Abstract

摘要： 目的分析布地奈德对感染诱发哮喘急性发作患儿趋化素样因子-1(CKLF-1)水平及免疫功能的影响,为临床防治提供理论依据。方法选取焦作市第二人民医院于2015年3月-2018年5月收治的100例感染诱发哮喘急性发作患儿的临床资料进行分析,分为两组。对照组采用常规治疗,观察组在对照组的基础上给予布地奈德治疗,分析两组患者治疗后的临床疗效。结果观察组患儿6周内、12周内日间症状及夜间症状积分低于对照组,急性发作次数少于对照组,差异有统计学意义(t=23.276、20.732、53.137、48.590、12.514,P<0.001)。两组患儿治疗前炎症因子、T淋巴细胞亚群、肺功能水平比较,差异无统计学意义(t=0.097、0.020、0.251、1.299、1.301、0.272、0.151、0.208、0.100、0.294,P＞0.05)。观察组患儿治疗后干扰素-γ(IFN-γ)、T淋巴细胞亚群、第1秒用力呼气容积(FEV₁)、肺活量(VC)、FEV₁占预计值百分比(FEV₁%)、用力肺活量(FVC)水平高于对照组,趋化素样因子-1(CKLF-1)、肿瘤坏死因子-α(TNF-α)、白介素-4(IL-4)水平低于对照组(t=3.940、7.707、7.740、3.909、5.289、17.220、3.885、6.932、5.028、19.941、17.665,P＜0.01)。结论布地奈德治疗感染诱发哮喘急性发作患儿,可降低CKLF-1、TNF-α、IL-4水平,增高IFN-γ水平,有效改善患儿临床症状、肺功能和免疫功能。

关键词: 布地奈德, 哮喘, 肺功能, 炎症因子

Abstract: Objective To analyze the effect of budesonide on the level of chemokin-like factor-1 (CKLF-1) and immune function in children with acute asthma induced by infection. Methods The clinical data of 100 cases of acute attack of infection-induced asthma treated in our hospital from March 2015 to May 2018 were selected for analysis, and were divided into two. The control group received routine treatment. The observation group was given with budesonide on the basis of the control group, and the clinical efficacy of the two groups of patients after treatment was analyzed. Results The scores of daytime and nighttime symptoms in the observation group were lower than those in the control group and the number of acute attacks was lower than those in the control group within 6 weeks and 12 weeks, and the difference was statistically significant (t=23.276,20.732,53.137,48.590,12.514,P<0.001).There were no statistically significant difference in levels of inflammatory cytokines, T-lymphocyte subsets and pulmonary function levels between the two groups before treatment (t=0.097,0.020,0.251,1.299,1.301,0.272,0.151,0.208,0.100,0.294,P＞0.05). After treatment, the levels of interferon (IFN-γ), T lymphocyte subsets, forced expiratory volume in 1 second (FEV1), vital capacity (VC), FEV1 percentage of expected value (FEV1 %), and the levels of forced vital capacity (FVC) were higher in the observation group observation group than the control group, chemotaxis sample factor 1 (CKLF-1), tumor necrosis factor alpha (TNF-α), interleukin 4 (IL-4) level were lower than those in the control group (t=3.940,7.707,7.740,3.909,5.289,17.220,3.885,6.932,5.028,19.941,17.665,P＜0.01). Conclusion The treatment of budesonide in children with acute attack of infection-induced asthma can reduce the IL-4 level of CKLF-1TNF-α, increase the level IFN-γ in patients, and effectively improve the clinical symptoms, lung function and immune function of children.

Key words: budesonide, asthma, lung function, inflammatory cytokines

中图分类号:

R725.6

王秀丽, 赵岩, 刘萍, 关丽霞. 布地奈德对感染诱发哮喘急性发作患儿趋化素样因子-1水平及免疫功能的影响[J]. 中国儿童保健杂志, 2020, 28(1): 100-103.

WANG Xiu-li, ZHAO Yan, LIU Ping, GUAN Li-xia. Effects of budesonide on the level and immune function of chemokin-like factor-1 in children with acute asthma induced by infection[J]. journal1, 2020, 28(1): 100-103.

参考文献

[1] 陈雅琴,李学明.布地奈德联合特布他林雾化吸入治疗小儿哮喘急性发作的临床疗效及对肺功能的影响分析[J].北方药学,2016,16(4):47-48.
[2] Ierodiaknou D,Zanobetti A,Coull BA,et al.Ambient air pollution,lungfunction,and airway responsiveness in asthmatic children[J].J Allergy Clin Immun,2016,137(2): 390-399.
[3] 杨春.布地奈德对哮喘急性发作且伴有感染患儿的临床疗效[J].儿科药学杂志,2018,24(8):14-17.
[4] 中华医学会儿科学分会呼吸学组,《中华儿科杂志》编委会.儿童支气管哮喘诊断与防治指南(2016年版)[J].中华儿科杂志,2016,54(3):167-181.
[5] Mcgeachie MJ,Yates KP,Zhou X,et al.Patterns of growth and decline in lung function in persistent childhood asthma[J].N Engl J Med,2016,374(19):1842-1852.
[6] 邹艳萍,罗小兰,刘利,等.布地奈德与丙酸倍氯米松辅助特布他林雾化吸入治疗小儿哮喘急性发作的对比研究[J].中国药房,2016,27(17):2388-2391.
[7] 潘焕,张云梅,蔡勇,等.布地奈德吸入联合过敏原特异性免疫疗法治疗支气管哮喘的临床效果[J].白求恩医学杂志,2016,14(3):309-310.
[8] Hoch HE,Szefler SJ.Intermittent steroid inhalation for the treatment of childhood asthma[J].Exp Rev Clin Immunol,2016,12(2):183-194.
[9] 张义堂,王中晓,杨红,等.布地奈德雾化吸入对小儿哮喘急性发作的临床观察[J].中国药房,2017,28(5):660-663.
[10] 姜明明,韩雪梅,于明涛.布地奈德对支气管哮喘患儿血清IL-4、CKLF-1和IFN-γ水平的影响[J].中国现代医生,2017,55(3):4-6.
[11] 庄林兵,吴格怡,刘旺,等.氯雷他定联合布地奈德雾化治疗对小儿支气管哮喘炎症因子影响研究[J].齐齐哈尔医学院学报,2016,37(6):785-786.
[12] 李海燕,郑有光,韩利红,等.难治性哮喘患者肺部感染病原菌分析及肺泡灌洗液与血清炎症因子水平[J].中华医院感染学杂志,2018,28(3):355-359.
[13] 张焕英,于连峰,杨俊玲,等.支气管哮喘患者血清肿瘤坏死因子-α和透明质酸及羟脯氨酸水平表达及意义[J].中华实用诊断与治疗杂志,2016,30(10):1022-1024.
[14] 王军,丁娟娟.孟鲁司特钠联合布地奈德混悬液对哮喘急性发作患儿C-反应蛋白,肺功能及临床疗效的影响[J].中国生化药物杂志,2016,5(2):108-110.
[15] 鲍志坚.乙酰半胱氨酸联合糖皮质激素对重度哮喘患者免疫功能及炎性因子的影响[J].中华全科医学,2017,15(8):1429-1432.
[16] 吴彪,庄探月,程东良,等.支气管哮喘合并感染性肺炎患儿对血小板指标、炎性因子水平及Th1/Th2比值的影响观察[J].中华医院感染学杂志,2016,26(24):5716-5719.